![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Gyr KE, Whitehouse I, Beglinger C, Köhler E, Dettwiler S, Fried M. Human pharmacological effects of SMS 201-995 on gastric secretion.
The inhibition of pentagastrin-stimulated- (3 μg kg−1 h−1) gastric acid secretion by various doses of intravenous and subcutaneous SMS 201-995, a somatostatin analogue, was investigated in healthy volunteers by means of gastric aspiration, using phenol red as a volume marker. The intravenous doses were compared with the standard dose of somatostatin-14, 3.5 μg kg−1 h−1. Similarly, SMS 201-995-induced inhibition of gastric acid secretion was compared with that of exocrine pancreatic secretion assessed by gastroduodenal aspiration. The results can be summarized as follows: 1) SMS 201-995 is a potent inhibitor of gastric acid secretion, exerting near maximal inhibition at a dose ≥0.56 μg kg−1 h−1. Near maximal inhibition equals that achieved with SST-14 (3.5 μg kg−1 h−1). 2) Pancreatic enzyme secretion appears to be strongly inhibited by lower doses of SMS 201-995 than gastric secretion. 3) Single subcutaneous injections of SMS 201-995 produce an inhibition of gastric acid secretion lasting for many hours. Near maximal inhibition was obtained with a dose of 100 μg.